NCT06585449 is a Phase 1 clinical trial of ALN-HTT02 in Huntington's Disease, sponsored by Alnylam Pharmaceuticals.

Who is sponsoring NCT06585449?

NCT06585449 is sponsored by Alnylam Pharmaceuticals.

What drugs are being tested in NCT06585449?

Interventions in NCT06585449: ALN-HTT02, Placebo.

What condition does NCT06585449 study?

NCT06585449 studies Huntington's Disease.

Is NCT06585449 still recruiting?

NCT06585449 is currently recruiting now. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT06585449

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Recruiting now Phase 1 Last updated 31 March 2026

What this trial tests

Phase 1 trial testing ALN-HTT02 in Huntington's Disease in 66 participants. Currently enrolling.

Timeline

14 October 2024

Primary endpoint
5 July 2028

5 July 2028

Quick facts

Lead sponsor	Alnylam Pharmaceuticals
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	66
Start date	14 October 2024
Primary completion	5 July 2028
Estimated completion	5 July 2028
Sites	19 locations across United Kingdom, Canada, Germany

Drugs / interventions tested

ALN-HTT02 — full drug profile →
Placebo

Conditions studied

Huntington's Disease — all drugs for Huntington's Disease →

Sponsor

Alnylam Pharmaceuticals — full company profile →

Who can join

Adults 25 to 70, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Huntington's Disease

Currently open trials in the same condition.

NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting

Other Alnylam Pharmaceuticals trials

Trials by the same sponsor.

NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06585449 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585449.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing